ArticleActa pharmaceutica Sinica. B2021
Intranasal temperature-sensitive hydrogels of cannabidiol inclusion complex for the treatment of post-traumatic stress disorder.
Article in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration-effect relations using the IB-de-risk tool.Journal of psychopharmacology (Oxford, England) · 2022Pooled it
- The effects of vaped cannabis on the severity of naloxone-precipitated opioid withdrawal.Experimental and clinical psychopharmacology · 2026Article
- Ion-Triggered In Situ Gel Combined with Melatonin Liposomes: Breaking Through the Dual Barriers of Nasal and Brain Delivery to Treat Insomnia.Pharmaceutics · 2026Article
- Multiple Roles of Cannabinoids in the Olfactory System.Brain sciences · 2026Review
- Cannabidiol: Pharmaceutical formulations and biomedical applications.Iranian journal of basic medical sciences · 2026Review
- Nanosystems for Intranasal Delivery of Therapeutics in Psychiatric Disorders.Current drug delivery · 2026Review
- Quantitation of Cannabidiol (CBD) in brain regions and plasma following intranasal administration of a CBD nanoformulation.Journal of cannabis research · 2025Article
- Solubilising and Aerosolising Cannabidiol Using Methyl β-Cyclodextrin and Human Serum Albumin.AAPS PharmSciTech · 2025Article
- Pharmacokinetics of Non-Psychotropic Phytocannabinoids.Pharmaceutics · 2025Review
- Temperature-sensitive Hydrogel: An Effective Treatment for Nasal Drug Delivery Targeting the Brain.Current drug metabolism · 2025Review
- Ribavirin in Modern Antitumor Therapy: Prospects for Intranasal Administration.Current drug delivery · 2025Review
- The Effects of Bioactive Compounds on PTSD Treatment.Current neuropharmacology · 2025Review
- Extracts ofInternational journal of medical sciences · 2025Article
- GPR17 modulates anxiety-like behaviorsActa pharmaceutica Sinica. B · 2024Article
- Single-Nucleus Transcriptome Profiling from the Hippocampus of a PTSD Mouse Model and CBD-Treated Cohorts.Genes · 2024Article
- Strategies to Improve Cannabidiol Bioavailability and Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Nanosuspension-Loaded Dissolving Microneedle Patches for Enhanced Transdermal Delivery of a Highly Lipophilic Cannabidiol.International journal of nanomedicine · 2024Article
- Current and future directions of drug delivery for the treatment of mental illnesses.Advanced drug delivery reviews · 2023Review
- Polymeric nanocarriers for nose-to-brain drug delivery in neurodegenerative diseases and neurodevelopmental disorders.Acta pharmaceutica Sinica. B · 2023Review
- The Improved Brain-Targeted Drug Delivery of Edaravone Temperature-Sensitive Gels by Ultrasound for γ-ray Radiation-Induced Brain Injury.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-traumatic stress disorder (PTSD) is a psychiatric disease that seriously affects brain function. Currently, selective serotonin reuptake inhibitors (SSRIs) are used to treat PTSD clinically but have decreased efficiency and increased side effects. In this study, nasal cannabidiol inclusion complex temperature-sensitive hydrogels (CBD TSGs) were prepared and evaluated to treat PTSD. Mice model of PTSD was established with conditional fear box. CBD TSGs could significantly improve the spontaneous behavior, exploratory spirit and alleviate tension in open field box, relieve anxiety and tension in elevated plus maze, and reduce the freezing time. Hematoxylin and eosin and c-FOS immunohistochemistry slides showed that the main injured brain areas in PTSD were the prefrontal cortex, amygdala, and hippocampus CA1. CBD TSGs could reduce the level of tumor necrosis factor-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.